Callos Andrew, an insider at Cytokinetics Inc (CYTK), sold 51,353 shares of the company on December 28, 2025, at a price of $62.44 per share. The total transaction value amounted to $3.21 million. Following this sale, Andrew retains 51,353 shares of Cytokinetics.
Cytokinetics is a biopharmaceutical company focused on developing treatments for diseases that compromise muscle performance. The firm is headquartered in South San Francisco, California, and currently employs 498 full-time staff. The company went public on April 29, 2004, and has a market capitalization of $7.4 billion with a trailing twelve-month earnings per share (EPS) of -6.31.
Upcoming earnings reports are scheduled for May 4, 2026, with an estimated EPS of -1.67 and revenue of $13.9 million, followed by another report on August 5, 2026, predicting an EPS of -1.66 and revenue of $24.4 million.
Insider transactions provide transparency into executive sentiment regarding company stock. However, they should be considered alongside other factors, as various personal or regulatory reasons may influence such decisions.